US EditionPublished • loading... • Updated
Abbott’s Esprit BTK Everolimus-eluting Resorbable Scaffold System Approved in Canada - Endovascular Today
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Abbott’s Esprit BTK Everolimus-eluting Resorbable Scaffold System Approved in Canada - Endovascular Today
October 2, 2025—Abbott announced that Health Canada has authorized the Esprit BTK everolimus-eluting resorbable scaffold system for the treatment of patients with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The company stated that the Esprit BTK system is a dissolvable stent that opens the blockage, then helps heal the vessel and provides support for approximately 3 years until the vessel is strong enough to remain open on its…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
